dc.date.accessioned2022-01-18T19:26:48Z
dc.date.available2022-01-18T19:26:48Z
dc.date.created2022-01-18T19:26:48Z
dc.date.issued2012
dc.identifierhttps://hdl.handle.net/20.500.12866/10894
dc.identifierhttps://doi.org/10.1016/j.vaccine.2012.01.058
dc.description.abstractTwo hundred female sex workers (FSWs) in Lima, Peru were randomized to receive HPV4 vaccine in the standard (0, 2, 6 months) or a modified schedule (0, 3, 6 months). One hundred and eighty four (92%) participants completed 3 doses of vaccine. Baseline seropositive rates were 58% for HPV6, 22.5% for HPV11, 41.5% for HPV16, and 13% for HPV18. The final geometric mean antibody titer (GMT) following vaccination was significantly greater for women who were seropositive at baseline compared to seronegative women: HPV6 (GMT ratio = 2.3, p< 0.01), HPV11 (GMT ratio = 2.7, p< 0.01), HPV16 (GMT ratio = 1.3, p= 0.04), and HPV18 (GMT ratio = 2.4, p< 0.01). Antibody titers in the modified schedule were not inferior to those in the standard schedule, suggesting the modified schedule may be paired with required STD visits. Although all women benefit from vaccination, administration at a younger age and before sexual debut is needed to achieve maximum protection from vaccine.
dc.languageeng
dc.publisherElsevier
dc.relationVaccine
dc.relation1873-2518
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHumans
dc.subjectPeru
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectmajor clinical study
dc.subjectpriority journal
dc.subjectsexual behavior
dc.subjectprostitution
dc.subjectSex Workers
dc.subjectTreatment Outcome
dc.subjectrandomized controlled trial
dc.subjectantibody response
dc.subjectantibody titer
dc.subjectVaccination
dc.subjectgroups by age
dc.subjectabsence of side effects
dc.subjectdrug response
dc.subjectcondyloma acuminatum
dc.subjectHuman papillomavirus type 11
dc.subjectHuman papillomavirus type 16
dc.subjectHuman papillomavirus type 18
dc.subjectHuman papillomavirus type 6
dc.subjectPapillomavirus Infections
dc.subjectPapillomavirus Vaccines
dc.subjectWart virus vaccine
dc.subjectuterine cervix cancer
dc.subjectdrug withdrawal
dc.subjectImmune response
dc.subjectAntibodies, Viral
dc.subjectHPV vaccine
dc.subjectFemale sex workers
dc.subjectHuman papillomavirus
dc.subjectvirus DNA
dc.subjectAlphapapillomavirus
dc.subjectAdherence
dc.subjectvirus antibody
dc.subjectcancer immunization
dc.subjectCervix Uteri
dc.subjectGammapapillomavirus
dc.subjectImmunization Schedule
dc.subjectvirus immunity
dc.titleRandomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución